Download the full article hronic neuropathic pain is estimated to be on the rise, particularly with the expected increase in patients with diabetes within the US. Diabetic and nondiabetic patients were surveyed for sick days fromwork due to neuropathic pain; approximately two-thirds of these patients were found to consistently be taking days from work, and…

ABSTRACT Mesenchymal stem cells (MSCs) are very attractive candidates in cell-based strategies that targetinflammatory diseases. Preclinical animal studies and many clinical trials have demonstrated thathuman MSCs can be safely administered and that they modify the inflammatory process in thetargeted injured tissue. Our laboratory developed a novel method that optimizes the anti-inflammatory effects of MSCs. We…

Objective: Mesenchymal stem cells (MSCs) have been shown in animal models to attenuatechronic neuropathic pain. This preliminary study investigated if: i) injections of autologousMSCs can reduce human neuropathic pain and ii) evaluate the safety of the procedure. Methods: Ten subjects with symptoms of neuropathic trigeminal pain underwent liposuction.The lipoaspirate was digested with collagenase and washed…

A nonphysiological repair of the lesioned nerve leading to the formation of neurinomas, altered nerveconduction, and spontaneous firing is considered the main cause of the events underlying neuropathicpain. It was investigated whether neural stem cell (NSCs) administration could lead to a physiologicalnerve repair, thus to a reduction of neuropathic pain symptoms such as hyperalgesia and…